Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Malaria: Epidemiology, prevention, and control

Joel G Breman, MD, DTPH
Section Editor
Johanna Daily, MD, MSc
Deputy Editor
Elinor L Baron, MD, DTMH


Malaria is endemic throughout most of the tropics. Ninety-five countries and territories have ongoing transmission [1]. Of the approximately 3.2 billion people living in malarious countries, 1.2 billion are at high risk; the World Health Organization (WHO) states that there were 214 million (range 149 to 303 million) cases of symptomatic malaria in 2015 (table 1).

Between 2000 and 2015, the incidence of malaria decreased by 32 percent, and the number of annual malaria cases estimated by the WHO decreased by 18 percent [1]. The vast majority of these cases and deaths are due to Plasmodium falciparum and occur in Africa, but Plasmodium vivax and Plasmodium knowlesi can also cause severe disease.

Important components for reducing the burden of malaria morbidity and mortality include more sensitive diagnostic tools, effective use of antimalarial drugs, improved personal and community protection, and mosquito control. The approach to elimination or control of malaria includes these basics, along with improvements in tracking of human illness and parasite surveillance, and effective resource delivery.

Issues related to epidemiology of malaria, including definitions and strategies for control, will be reviewed. Other related topics are discussed in detail separately. (See related topics.)


Overview — Malaria is transmitted via the bite of a female Anopheles spp mosquito, which occurs mainly between dusk and dawn. Other comparatively rare mechanisms for transmission include congenitally acquired disease, blood transfusion, sharing of contaminated needles, organ transplantation, and nosocomial transmission [2-4].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Oct 30, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. World Health Organization. World Malaria Report 2015. WHO, Geneva 2015. http://www.who.int/malaria/publications/world_malaria_report_2015/report/en/ (Accessed on August 01, 2016).
  2. Owusu-Ofori AK, Betson M, Parry CM, et al. Transfusion-transmitted malaria in Ghana. Clin Infect Dis 2013; 56:1735.
  3. Mace KE, Arguin PM. Malaria Surveillance - United States, 2014. MMWR Surveill Summ 2017; 66:1.
  4. Gruell H, Hamacher L, Jennissen V, et al. On Taking a Different Route: An Unlikely Case of Malaria by Nosocomial Transmission. Clin Infect Dis 2017; 65:1404.
  5. Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379:413.
  6. Gething PW, Casey DC, Weiss DJ, et al. Mapping Plasmodium falciparum Mortality in Africa between 1990 and 2015. N Engl J Med 2016; 375:2435.
  7. Guerra CA, Gikandi PW, Tatem AJ, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008; 5:e38.
  8. Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434:214.
  9. Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77:79.
  10. Breman JG. Eradicating malaria. Sci Prog 2009; 92:1.
  11. White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis 2008; 46:172.
  12. Smith T, Maire N, Dietz K, et al. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am J Trop Med Hyg 2006; 75:11.
  13. Kiszewski AE, Teklehaimanot A. A review of the clinical and epidemiologic burdens of epidemic malaria. Am J Trop Med Hyg 2004; 71:128.
  14. WHO Global Malaria Control and Elimination: report of a technical review 17-18 January 2008. Geneva, pp. 1-47.
  15. Bruce Chwatt LJ. Essential Malariology, Wiley Medical, 1985. p.193.
  16. Laufer MK, Takala-Harrison S, Dzinjalamala FK, et al. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis 2010; 202:801.
  17. Sturrock HJ, Novotny JM, Kunene S, et al. Reactive case detection for malaria elimination: real-life experience from an ongoing program in Swaziland. PLoS One 2013; 8:e63830.
  18. Breman JG, Holloway CN. Malaria surveillance counts. Am J Trop Med Hyg 2007; 77:36.
  19. malERA Consultative Group on Health Systems and Operational Research. A research agenda for malaria eradication: health systems and operational research. PLoS Med 2011; 8:e1000397.
  20. Noor AM, Kinyoki DK, Mundia CW, et al. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity. Lancet 2014; 383:1739.
  21. Greenwood B, Koram K. Malaria control in Africa: progress but still much to do. Lancet 2014; 383:1703.
  22. Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015; 526:207.
  23. Nayyar GM, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012; 12:488.
  24. http://www.searo.who.int/mediacentre/releases/2016/1631/en/ (Accessed on September 20, 2016).
  25. Skarbinski J, Ouma PO, Causer LM, et al. Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial. Am J Trop Med Hyg 2009; 80:919.
  26. Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 2001; 64:1.
  27. Alonso PL, Brown G, Arevalo-Herrera M, et al. A research agenda to underpin malaria eradication. PLoS Med 2011; 8:e1000406.
  28. World Health Organization. Global Technical Strategy for Malaria 2016–2030. WHO, Geneva 2016. http://www.who.int/malaria/areas/global_technical_strategy/en/ (Accessed on August 01, 2016).
  29. WHO, World Malaria Report, 2008. Geneva, Switzerland.
  30. Debboun M, Frances SP, Strickman D. Insect Repellents, CRC Press, Boca Raton 2007.
  31. Hill N, Lenglet A, Arnéz AM, Carneiro I. Plant based insect repellent and insecticide treated bed nets to protect against malaria in areas of early evening biting vectors: double blind randomised placebo controlled clinical trial in the Bolivian Amazon. BMJ 2007; 335:1023.
  32. Rowland M, Downey G, Rab A, et al. DEET mosquito repellent provides personal protection against malaria: a household randomized trial in an Afghan refugee camp in Pakistan. Trop Med Int Health 2004; 9:335.
  33. Curtis CF, Maxwell CA, Magesa SM, et al. Insecticide-treated bed-nets for malaria mosquito control. J Am Mosq Control Assoc 2006; 22:501.
  34. Velema JP. Malaria, bednets, and mortality. Lancet 1991; 338:642.
  35. Wang D, Kamijima M, Imai R, et al. Biological monitoring of pyrethroid exposure of pest control workers in Japan. J Occup Health 2007; 49:509.
  36. Lengeler C. Insecticide-treated bednets and curtains for preventing malaria. Cochrane Database Syst Rev 2000; :CD000363.
  37. Zaim M, Aitio A, Nakashima N. Safety of pyrethroid-treated mosquito nets. Med Vet Entomol 2000; 14:1.
  38. Lindblade KA, Eisele TP, Gimnig JE, et al. Sustainability of reductions in malaria transmission and infant mortality in western Kenya with use of insecticide-treated bednets: 4 to 6 years of follow-up. JAMA 2004; 291:2571.
  39. Askjaer N, Maxwell C, Chambo W, et al. Insecticide-treated bed nets reduce plasma antibody levels and limit the repertoire of antibodies to Plasmodium falciparum variant surface antigens. Clin Diagn Lab Immunol 2001; 8:1289.
  40. Henry MC, Assi SB, Rogier C, et al. Protective efficacy of lambda-cyhalothrin treated nets in Anopheles gambiae pyrethroid resistance areas of Côte d'Ivoire. Am J Trop Med Hyg 2005; 73:859.
  41. Trape JF, Tall A, Diagne N, et al. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis 2011; 11:925.
  42. Asidi A, N'Guessan R, Akogbeto M, et al. Loss of household protection from use of insecticide-treated nets against pyrethroid-resistant mosquitoes, benin. Emerg Infect Dis 2012; 18:1101.
  43. Curtis CF, Maxwell CA, Finch RJ, Njunwa KJ. A comparison of use of a pyrethroid either for house spraying or for bednet treatment against malaria vectors. Trop Med Int Health 1998; 3:619.
  44. Hemingway J, Ranson H, Magill A, et al. Averting a malaria disaster: will insecticide resistance derail malaria control? Lancet 2016; 387:1785.
  45. Pinder M, Jawara M, Jarju LB, et al. Efficacy of indoor residual spraying with dichlorodiphenyltrichloroethane against malaria in Gambian communities with high usage of long-lasting insecticidal mosquito nets: a cluster-randomised controlled trial. Lancet 2015; 385:1436.
  46. Lines J, Kleinschmidt I. Is malaria control better with both treated nets and spraying? Lancet 2015; 385:1375.
  47. World Health Organizatoin, Chemotherapy of malaria, 2015.
  48. Crawley J, Sismanidis C, Goodman T, et al. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials. Lancet 2012; 380:1001.
  49. World Health Organization. Guidelines for the treatment of malaria, 3rd ed, WHO, Geneva 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/ (Accessed on September 10, 2015).
  50. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009; 374:1533.
  51. Gosling RD, Gesase S, Mosha JF, et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1521.
  52. Benn CS, Aaby P. Does IPTi decrease malaria morbidity but not mortality? Lancet 2012; 380:958.
  53. Pearce RJ, Ord R, Kaur H, et al. A community-randomized evaluation of the effect of intermittent preventive treatment in infants on antimalarial drug resistance in southern Tanzania. J Infect Dis 2013; 207:848.
  54. WHO. Report of the Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi), Technical Expert Group on Preventive Chemotherapy, Geneva: WHO 2009:1-11. http://www.who.int/malaria/publications/atoz/tegconsultiptiapr2009report.pdf (Accessed on March 13, 2013).
  55. World Health Organization, United Nations Children’s Fund. Cotrimoxazole prophylaxis for HIV-exposed and HIV-infected infants and children: practical approaches to implementation and scale up. Geneva, Switzerland: WHO/UNICEF, 2009.
  56. Davis NL, Barnett EJ, Miller WC, et al. Impact of daily cotrimoxazole on clinical malaria and asymptomatic parasitemias in HIV-exposed, uninfected infants. Clin Infect Dis 2015; 61:368.
  57. Meremikwu MM, Donegan S, Sinclair D, et al. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev 2012; :CD003756.
  58. Cissé B, Ba EH, Sokhna C, et al. Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. PLoS Med 2016; 13:e1002175.
  59. Nankabirwa JI, Wandera B, Amuge P, et al. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis 2014; 58:1404.
  60. Athuman M, Kabanywanyi AM, Rohwer AC. Intermittent preventive antimalarial treatment for children with anaemia. Cochrane Database Syst Rev 2015; 1:CD010767.
  61. Portugal S, Tran TM, Ongoiba A, et al. Treatment of Chronic Asymptomatic Plasmodium falciparum Infection Does Not Increase the Risk of Clinical Malaria Upon Reinfection. Clin Infect Dis 2017; 64:645.
  62. Eisele TP, Bennett A, Silumbe K, et al. Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial. J Infect Dis 2016; 214:1831.
  63. Björkman A, Cook J, Sturrock H, et al. Spatial Distribution of Falciparum Malaria Infections in Zanzibar: Implications for Focal Drug Administration Strategies Targeting Asymptomatic Parasite Carriers. Clin Infect Dis 2017; 64:1236.
  64. Abdulla S, Oberholzer R, Juma O, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008; 359:2533.
  65. Breman JG, Plowe CV. A malaria vaccine for control: more progress. J Infect Dis 2009; 200:317.
  66. Agnandji ST, Asante KP, Lyimo J, et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 2010; 202:1076.
  67. RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863.
  68. RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284.
  69. Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 2013; 368:1111.
  70. Bejon P, White MT, Olotu A, et al. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 2013; 13:319.
  71. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386:31.
  72. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521.
  73. Olotu A, Fegan G, Wambua J, et al. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. N Engl J Med 2016; 374:2519.
  74. Neafsey DE, Juraska M, Bedford T, et al. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med 2015; 373:2025.
  75. Katureebe A, Zinszer K, Arinaitwe E, et al. Measures of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor Residual Spraying at Three Sites in Uganda: A Prospective Observational Study. PLoS Med 2016; 13:e1002167.
  76. Hamon J. Les moustiques anthropophiles de la région de Bobo Dioulasso: cycles d'aggressivité et variations saisonnières. Annales de la Societé d'Entomologie de la France 1963; 132:85.
  77. Pates H, Curtis C. Mosquito behavior and vector control. Annu Rev Entomol 2005; 50:53.
  78. Curtis CF. Integrated vector management for malaria. In: Integrated Pest Management, Radcliffe E (Ed), Cambridge University Press, Cambridge 2008.
  79. Rowland M, Mohammed N, Rehman H, et al. Anopheline vectors and malaria transmission in eastern Afghanistan. Trans R Soc Trop Med Hyg 2002; 96:620.
  80. Van Bortel W, Trung HD, Thuan le K, et al. The insecticide resistance status of malaria vectors in the Mekong region. Malar J 2008; 7:102.
  81. Chandre F, Darrier F, Manga L, et al. Status of pyrethroid resistance in Anopheles gambiae sensu lato. Bull World Health Organ 1999; 77:230.
  82. Clements AN. The Biology of Mosquitoes, Chapman and Hall, 1992. Vol Volume 1.
  83. World Health Organization. Manual for indoor residual spraying application of residual sprays for vector control. WHO/CDS/WHOPES/GCDPP/2000.3 Rev.1.
  84. Sadasivaiah S, Tozan Y, Breman JG. Dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying in Africa: how can it be used for malaria control? Am J Trop Med Hyg 2007; 77:249.
  85. Roberts DR, Alecrim WD. Behavioral response of Anopheles darlingi to DDT-sprayed house walls in Amazonia. Bull Pan Am Health Organ 1991; 25:210.
  86. MacDonald G. Epidemiology and Control of Malaria, Oxford University Press, London 1957.
  87. Stockholm Convention on Persistent Organic Pollutants. http://chm.pops.int/ (Accessed on September 01, 2009).
  88. Giglioli G. Changes in the pattern of mortality following the eradication of hyperendemic malaria from a highly susceptible community. Bull World Health Organ 1972; 46:181.
  89. Maharaj R, Mthembu DJ, Sharp BL. Impact of DDT re-introduction on malaria transmission in KwaZulu-Natal. S Afr Med J 2005; 95:871.
  90. Raouf S, Mpimbaza A, Kigozi R, et al. Resurgence of Malaria Following Discontinuation of Indoor Residual Spraying of Insecticide in an Area of Uganda With Previously High-Transmission Intensity. Clin Infect Dis 2017; 65:453.
  91. Ghosh SK, Tiwari SN, Sathyanarayan TS, et al. Larvivorous fish in wells target the malaria vector sibling species of the Anopheles culicifacies complex in villages in Karnataka, India. Trans R Soc Trop Med Hyg 2005; 99:101.
  92. Yapabandara AM, Curtis CF, Wickramasinghe MB, Fernando WP. Control of malaria vectors with the insect growth regulator pyriproxyfen in a gem-mining area in Sri Lanka. Acta Trop 2001; 80:265.
  93. Fillinger U, Lindsay SW. Suppression of exposure to malaria vectors by an order of magnitude using microbial larvicides in rural Kenya. Trop Med Int Health 2006; 11:1629.
  94. Andreasen MH, Curtis CF. Optimal life stage for radiation sterilization of Anopheles males and their fitness for release. Med Vet Entomol 2005; 19:238.
  95. Klassen W, Curtis CF. History of the Sterile Insect Technique (SIT). In: The Sterile Insect Technique: Principles and Practice in Area-wide Integrated Pest Management, Dyck VA, Hendrichs L, Robinson AS (Eds), Springer, Heidelberg, Germany 2005. p.3.
  96. Catteruccia F, Benton JP, Crisanti A. An Anopheles transgenic sexing strain for vector control. Nat Biotechnol 2005; 23:1414.
  97. Ito J, Ghosh A, Moreira LA, et al. Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite. Nature 2002; 417:452.
  98. Chen CH, Huang H, Ward CM, et al. A synthetic maternal-effect selfish genetic element drives population replacement in Drosophila. Science 2007; 316:597.
  99. Burt A, Trivers R. Genes in Conflict, Belknap Press, Harvard University, 2006.
  100. Curtis CF, Coleman PG, Kelly D. Advantages and limitations of transgenic vector control: sterile males versus gene drivers. In: Genetically Modified Mosquitoes for Malaria Control, Boete C (Ed), Landes Bioscience, Georgetown, Texas 2006. p.60.
  101. Ouédraogo AL, Bastiaens GJ, Tiono AB, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis 2015; 60:357.
  102. http://www.who.int/maternal_child_adolescent/documents/iron_statement/en/ (Accessed on September 17, 2013).
  103. Zlotkin S, Newton S, Aimone AM, et al. Effect of iron fortification on malaria incidence in infants and young children in Ghana: a randomized trial. JAMA 2013; 310:938.
  104. Neuberger A, Okebe J, Yahav D, Paul M. Oral iron supplements for children in malaria-endemic areas. Cochrane Database Syst Rev 2016; 2:CD006589.